Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: A safer and more effective treatment

Hormone Research

Volumn 55, Issue 5, 2001, Pages 224-228

  Fulghesu, Anna Maria ^a   Apa, Rosanna ^a   Belosi, Chiara ^a   Ciampelli, Mario ^a   Selvaggi, Jr , Luigi ^a   Cucinelli, Francesco ^a   Caruso, Alessandro ^a   Mancuso, Salvatore ^a   Lanzone, Antonio ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Follicle stimulating hormone, urinary; Low dose protocol; Ovarian hyperstimulation syndrome; Ovulation induction; Polycystic ovarian syndrome; Recombinant follicle stimulating hormone

Indexed keywords

ESTRADIOL; RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ADULT; AMPOULE; ANOVULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; INCIDENCE; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANOVULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; RECOMBINANT PROTEINS; SAFETY; URINE;

EID: 0035217110     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050000     Document Type: Article

References (20)

1. Epidemiology of infertility and polycystic ovarian disease: Endocrinological and demographic studies
2. A decade's experience with an individualized clomiphene treatment regimen including its effects on the post-coital test
3. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles
4. Polycystic ovary syndrome: The spectrum of the disorder in 1,714 patients
5. Purified follicle-stimulating hormone in polycystic ovary syndrome: Slow administration is safer and more effective
6. Effects of recombinant human follicle stimulating hormone on cultured human granulosa cells: Comparison with urinary gonadotropins and actions in preovulatory follicles
7. Ovarian hyperstimulation syndrome: An update review
8. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®)
9. Structure-function relationship of recombinant follicle stimulating hormone (Puregon®)
10. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon®): Relationship between serum FSH and efficacy
11. Biological characterization of the isoforms of urinary human follicle-stimulating hormone (Org 32489) in gonadotropin-deficient volunteers
12. A prospective, randomized, assessor-blind, multicenter study comparing recombinant and urinary follicle-stimulating hormone (Puregon vs. Metrodin) in in-vitro fertilization
13. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome
14. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: A prospective, multicenter, assessor-blind, randomized, clinical trial
15. Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency
16. Clinical assessment of recombinant human follicle-stimulating ovarian follicular development before in vitro fertilization
17. The effect of human menopausal gonadotropin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women
18. Use of recombinant FSH in assisted reproduction